MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...
Hosted on MSN11d
New antibody reduces tumor growth in tough-to-treat breast and ovarian cancers: StudyHER2 is responsible for cancer growth and is the target of existing therapies, such as the most commonly used type of ...
Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.
An antibody discovery platform revealed more than 60 monoclonal antibodies specific to patients with alpha-gal syndrome, ...
The following is a summary of “Kinetics of tick-borne encephalitis virus IgM antibody responses in serum and cerebrospinal ...
Recent study conducted by Caushi et al. aimed to evaluate the role of Elisa IgG serum antibody titres in diagnosing pulmonary ...
Researchers at King's College London have developed IgE antibodies targeting HER2-expressing cancers. Early studies show ...
Bispecific antibodies (BsAbs) have emerged as a transformative class of biologics, offering dual-targeting mechanisms that enhance therapeutic efficacy across oncology, autoimmune disorders, and ra | ...
Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug conjugate (ADC) linker platform.
The FDA has granted fast-track designation to nipocalimab for the treatment of Sjögren’s disease, according to a press ...
Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback